Therapeutic potential of melatonin in cancer treatment;Potentiel thérapeutique de la mélatonine dans la prise en charge de la pathologie cancéreuse

Pathologie Biologie

Volumn 53, Issue 5, 2005, Pages 265-268

  Abrial, C ^a   Kwiatkowski, F ^a   Chevrier, R ^a   Gachon, F ^a   Cure H ^a   Chollet, P ^a  

^a INSERM   (France)

Author keywords

Immune System; Melatonin; Metastatic breast cancer; Rhythms

Indexed keywords

MELATONIN; MELATONIN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER; CANCER THERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; MOLECULAR INTERACTION; PINEAL BODY; SLEEP INDUCTION; THROMBOCYTOPENIA;

CIRCADIAN RHYTHM; HUMANS; MELATONIN; NEOPLASMS; PINEAL GLAND; RECEPTORS, MELATONIN; SLEEP;

EID: 20444430497     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.12.009     Document Type: Article

References (30)

1. J.B. Fourtillan, A.M. Brisson, P. Gobin, I. Ingrand, J.P. Decourt, and J. Girault Bioavailability of melatonin in humans after day-time administration of D(7) melatonin Biopharm. Drug. Dispos. 21 1 2000 15 22 Jan
2. P.A. Witt-Enderby, J. Bennett, M.J. Jarzynka, S. Firestine, and M.A. Melan Melatonin receptors and their regulation: biochemical and structural mechanisms Life Sciences 72 20 2003 2183 2198 Apr 4
3. P. Pevet Ḿlatonine et rythmes biologiques Therapie 53 1998 411 420
4. C. Von Gall, J.H. Stehle, and D.R. Weaver Mammalian melatonin receptors: molecular biology and signal transduction Cell. Tissue Res. 309 2002 151 162 Apr 2
5. B. Neri, V. De Leonardis, M.T. Gemelli, F. Di loro, A. Mottola, and R. Ponchietti Melatonin as biological response modifier in cancer patients Anticancer Res. 18 2B 1998 1329 1332
6. G.J. Maestroni MLT and the immune-hematopoietic system Adv. Exp. Med. Biol. 460 1999 395 405
7. G.J. Maestroni Therapeutic potential of melatonin in immunodeficiency states, viral diseases and cancer Adv. Exp. Med. Biol. 467 1999 217 226
8. E. Haus Biologic rhythms in hematology Pathol. Biol. 44 7 1996 618 630
9. E. Haus, and M.H. Smolensky Biologic rhythms in the immune system Chronobiol. Int. 16 5 1999 581 622
10. N.L. Currier, L.Z.Y. Sun, and S.C. Miller Exogenous melatonin: quantitative enhancement in vivo of cells mediating non-specific immunity Journal of Neuroimmunology 104 2 2000 101 108 May 1
11. M. Koc, M.E. Buyukokuroglu, and S. Taysi The effect of melatonin on peripheral blood cells during total body irradiation in rats Biol. Pharm. Bull. 25 5 May 2002 656 657
12. Vijayalaxmi, M.L. Meltz, R.J. Reiter, and T.S. Herman Melatonin and protection from genetic damage in blood and bone marrow: whole-body irradiation studies in mice J. Pineal Res. 27 4 1999 221 225
13. P. Lissoni, G. Tancini, S. Barni, F. Paolorossi, A. Ardizzoia, and A. Conti Support. Care Cancer 5 2 1997 126 129
14. G.J. Maestroni, V. Covacci, and A. Conti Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice Cancer Res. 54 9 1994 2429 2432
15. G.A. Bubenik, D.E. Blask, G.M. Brown, G.J. Maestroni, S.F. Pang, and R.J. Reiter Prospects of the clinical utilization of melatonin Biol. Signals Recept. 7 4 1998 195 219
16. M. Pawlikowski, K. Winczyk, and M. Karasek Oncostatic action of melatonin:: facts and question marks Neuroendocrinol. Lett. 23 Suppl 1 April 2002 24 29
17. K. Winczyk, M. Pawlikowski, and M. Karasek Melatonin and RZR/ROR receptor ligand CGP 52608 induce apoptosis in the murine colonic cancer J. Pineal. Res. 31 2 September 2001 179 182
18. D.E. Blask, L.A. Sauer, and R.T. Dauchy Melatonin as a chronobiotic/anticancer agent:: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy Curr. Top. Med. Chem. 2 2 February 2002 113 132
19. M.M. Horowitz, R.P. Gale, and P.N. Sonde Graft versus leukemia reactions after bone marrow transplantation Blood 75 1990 555 562
20. P. Lissoni, G. Tancini, S. Barni, F. Paolorossi, F. Rossini, and P. Maffe The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia Recenti Prog. Med. 87 12 1996 582 585
21. P. Lissoni, S. Barni, F. Brivio, F. Rossini, L. Fumagalli, and G. Tancini Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study J. Biol. Regul. Homeost. Agents 9 2 1995 52 54
22. P. Lissoni, S. Barni, F. Brivio, F. Rossini, L. Fumagalli, and A. Ardizzoia A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia Oncology 52 5 1995 360 362
23. P. Lissoni, S. Barni, A. Ardizzoia, F. Brivio, G. Tancini, and A. Conti Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients J. Biol. Reg. Homeos. Agents. 6 1992 132 136
24. B. Neri, C. Fiorelli, F. Moroni, G. Nicita, M.C. Paoletti, and R. Ponchietti Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study Cancer 75 1994 3015 3019
25. U.D. Rohr, and J. Herold Melatonin deficiencies in women Maturitas 41 Suppl 1 2002 85 104
26. D. Garfinkel, M. Laudon, D. Nof, and N. Zisapel Improvement of sleep quality in elderly people by controlled-release melatonin Lancet 346 1995 541 544
27. P. Lissoni, G. Tancini, F. Paolorossi, M. Mandala, A. Ardizzoia, and F. Malugani Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study J. Pineal Res. 26 1999 169 173
28. P. Lissoni, S. Barni, M. Mandala, A. Ardizzoia, F. Paolorossi, and M. Vaghi Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status Eur. J. Cancer 35 12 1999 1688 1692
29. G. Cerea, M. Vaghi, A. Ardizzoia, S. Villa, R. Bucovec, and S. Mengo Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer. Res. 23 2C 2003 1951 1954
30. P. Lissoni, F. Paolorossi, A. Ardizzoia, S. Barni, M. Chilelli, and M. Mancuso A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state J. Pineal Res. 23 1 1997 15 19